Enasidenib Targeted Therapy Guide: IDH2 Mutant AML Patient Medication Details

　　Enasidenib(brand name Idhifa)belongs to the oral IDH2 inhibitor class of medications,representing the globally first approved isocitrate dehydrogenase 2 targeted therapy drug.This medication provides innovative treatment solutions specifically for adult patients with relapsed or refractory acute myeloid leukemia carrying IDH2 gene mutations.

　　1.Pharmacological Mechanism

　　This medication works by precisely inhibiting the biological activity of mutant IDH2 enzymes,effectively blocking the synthesis pathway of abnormal metabolite 2-hydroxyglutarate.In patients with IDH2 mutant acute myeloid leukemia,excessive accumulation of 2-hydroxyglutarate interferes with the normal maturation process of hematopoietic cells,promoting uncontrolled proliferation of leukemia cells.Enasidenib promotes gradual differentiation of abnormal immature cells toward mature blood cells through targeted inhibition of mutant IDH2 enzymes.This unique"differentiation induction"treatment model becomes the core advantage of this drug in the leukemia treatment field.

　　2.Applicable Patient Population

　　This product is suitable for adult patients with relapsed or refractory acute myeloid leukemia confirmed to have IDH2 mutations through genetic testing.IDH2 mutation status testing must be completed before medication use,which is a critical step for achieving precision medicine.For newly diagnosed IDH2 mutant acute myeloid leukemia patients,Enasidenib can also serve as one of the treatment option choices.

　　3.Clinical Efficacy Performance

　　Multiple clinical trial data indicate that Enasidenib demonstrates good therapeutic effects in patient populations with IDH2 mutant relapsed or refractory acute myeloid leukemia.Some patients can achieve complete remission or partial remission status,with significant extension of overall survival time.For elderly patient populations unable to tolerate intensive chemotherapy regimens,Enasidenib provides a relatively gentle alternative treatment option.

　　4.Dosing Regimen Instructions

　　The recommended initial medication dose is 100 milligrams daily,administered as a single oral dose.Medication can be taken with meals or in fasting state.Tablets must be swallowed whole;cutting,crushing or chewing is prohibited.During the treatment process,medical professionals may adjust dosage based on patient treatment response and tolerance levels.

　　5.Adverse Reaction Management

　　Common adverse reactions include nausea,vomiting responses,diarrhea symptoms,body fatigue,appetite reduction and other manifestations.Special attention is needed as this medication may trigger differentiation syndrome,with clinical manifestations including fever symptoms,respiratory distress,weight gain,limb edema and other signs requiring timely identification and intervention measures.Other possible adverse reactions include elevated white blood cell counts,decreased platelet numbers,anemia and other hematological system abnormal manifestations.

　　6.Special Population Medication Guidelines

　　For patients with moderate to severe liver function or kidney function impairment using Enasidenib,dosage adjustments require extra caution.Patients of childbearing age should adopt reliable contraceptive measures during medication use and after discontinuation.This medication can cross the placenta and may cause potential harm to the fetus;pregnant women are prohibited from use.